FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067288984> ?p ?o ?g. }

• W2067288984 endingPage "707" @default.
• W2067288984 startingPage "701" @default.
• W2067288984 abstract "Purpose To examine the prognostic significance of c-Met expression in relation to p16 and epidermal growth factor receptor (EGFR) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive concurrent chemoradiation. Methods and Materials Archival tissue from 107 HNSCC patients treated with chemoradiation was retrieved, and a tissue microarray was assembled. Immunohistochemical staining of c-Met, p16, and EGFR was performed. c-Met expression was correlated with p16, EGFR, clinical characteristics, and clinical endpoints including locoregional control (LRC), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS). Results Fifty-one percent of patients were positive for p16, and 53% were positive for EGFR. Both p16-negative (P≤.001) and EGFR-positive (P=.019) status predicted for worse DFS. Ninety-three percent of patients stained positive for c-Met. Patients were divided into low (0, 1, or 2+ intensity) or high (3+ intensity) c-Met expression. On univariate analysis, high c-Met expression predicted for worse LRC (hazard ratio [HR] 2.27; 95% CI, 1.08-4.77; P=.031), DM (HR 4.41; 95% CI, 1.56-12.45; P=.005), DFS (HR 3.00; 95% CI, 1.68-5.38; P<.001), and OS (HR 4.35; 95% CI, 2.13-8.88; P<.001). On multivariate analysis, after adjustment for site, T stage, smoking history, and EGFR status, only high c-Met expression (P=.011) and negative p16 status (P=.003) predicted for worse DFS. High c-Met expression was predictive of worse DFS in both EGFR-positive (P=.032) and -negative (P=.008) patients. In the p16-negative patients, those with high c-Met expression had worse DFS (P=.036) than did those with low c-Met expression. c-Met expression was not associated with any outcome in the p16-positive patients. Conclusions c-Met is expressed in the majority of locally advanced HNSCC cases, and high c-Met expression predicts for worse clinical outcomes. High c-Met expression predicted for worse DFS in p16-negative patients but not in p16-positive patients. c-Met predicted for worse outcome regardless of EGFR status. To examine the prognostic significance of c-Met expression in relation to p16 and epidermal growth factor receptor (EGFR) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive concurrent chemoradiation. Archival tissue from 107 HNSCC patients treated with chemoradiation was retrieved, and a tissue microarray was assembled. Immunohistochemical staining of c-Met, p16, and EGFR was performed. c-Met expression was correlated with p16, EGFR, clinical characteristics, and clinical endpoints including locoregional control (LRC), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS). Fifty-one percent of patients were positive for p16, and 53% were positive for EGFR. Both p16-negative (P≤.001) and EGFR-positive (P=.019) status predicted for worse DFS. Ninety-three percent of patients stained positive for c-Met. Patients were divided into low (0, 1, or 2+ intensity) or high (3+ intensity) c-Met expression. On univariate analysis, high c-Met expression predicted for worse LRC (hazard ratio [HR] 2.27; 95% CI, 1.08-4.77; P=.031), DM (HR 4.41; 95% CI, 1.56-12.45; P=.005), DFS (HR 3.00; 95% CI, 1.68-5.38; P<.001), and OS (HR 4.35; 95% CI, 2.13-8.88; P<.001). On multivariate analysis, after adjustment for site, T stage, smoking history, and EGFR status, only high c-Met expression (P=.011) and negative p16 status (P=.003) predicted for worse DFS. High c-Met expression was predictive of worse DFS in both EGFR-positive (P=.032) and -negative (P=.008) patients. In the p16-negative patients, those with high c-Met expression had worse DFS (P=.036) than did those with low c-Met expression. c-Met expression was not associated with any outcome in the p16-positive patients. c-Met is expressed in the majority of locally advanced HNSCC cases, and high c-Met expression predicts for worse clinical outcomes. High c-Met expression predicted for worse DFS in p16-negative patients but not in p16-positive patients. c-Met predicted for worse outcome regardless of EGFR status." @default.
• W2067288984 created "2016-06-24" @default.
• W2067288984 creator A5004874300 @default.
• W2067288984 creator A5010037979 @default.
• W2067288984 creator A5011309644 @default.
• W2067288984 creator A5038871228 @default.
• W2067288984 creator A5041234276 @default.
• W2067288984 creator A5056267232 @default.
• W2067288984 creator A5081017832 @default.
• W2067288984 creator A5090357414 @default.
• W2067288984 date "2014-03-01" @default.
• W2067288984 modified "2023-10-06" @default.
• W2067288984 title "c-Met Expression Is a Marker of Poor Prognosis in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Chemoradiation" @default.
• W2067288984 cites W1974058738 @default.
• W2067288984 cites W1998370121 @default.
• W2067288984 cites W1998516111 @default.
• W2067288984 cites W2004439203 @default.
• W2067288984 cites W2015307495 @default.
• W2067288984 cites W2058191258 @default.
• W2067288984 cites W2062110561 @default.
• W2067288984 cites W2089257078 @default.
• W2067288984 cites W2091775645 @default.
• W2067288984 cites W2108718020 @default.
• W2067288984 cites W2110664940 @default.
• W2067288984 cites W2117750856 @default.
• W2067288984 cites W2125252512 @default.
• W2067288984 cites W2133734904 @default.
• W2067288984 cites W2142869330 @default.
• W2067288984 cites W2143680521 @default.
• W2067288984 cites W2145478177 @default.
• W2067288984 cites W2151730005 @default.
• W2067288984 cites W2155598934 @default.
• W2067288984 cites W2158508310 @default.
• W2067288984 cites W2167685509 @default.
• W2067288984 doi "https://doi.org/10.1016/j.ijrobp.2013.11.013" @default.
• W2067288984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24521684" @default.
• W2067288984 hasPublicationYear "2014" @default.
• W2067288984 type Work @default.
• W2067288984 sameAs 2067288984 @default.
• W2067288984 citedByCount "40" @default.
• W2067288984 countsByYear W20672889842014 @default.
• W2067288984 countsByYear W20672889842015 @default.
• W2067288984 countsByYear W20672889842016 @default.
• W2067288984 countsByYear W20672889842017 @default.
• W2067288984 countsByYear W20672889842018 @default.
• W2067288984 countsByYear W20672889842019 @default.
• W2067288984 countsByYear W20672889842020 @default.
• W2067288984 countsByYear W20672889842021 @default.
• W2067288984 countsByYear W20672889842022 @default.
• W2067288984 countsByYear W20672889842023 @default.
• W2067288984 crossrefType "journal-article" @default.
• W2067288984 hasAuthorship W2067288984A5004874300 @default.
• W2067288984 hasAuthorship W2067288984A5010037979 @default.
• W2067288984 hasAuthorship W2067288984A5011309644 @default.
• W2067288984 hasAuthorship W2067288984A5038871228 @default.
• W2067288984 hasAuthorship W2067288984A5041234276 @default.
• W2067288984 hasAuthorship W2067288984A5056267232 @default.
• W2067288984 hasAuthorship W2067288984A5081017832 @default.
• W2067288984 hasAuthorship W2067288984A5090357414 @default.
• W2067288984 hasConcept C126322002 @default.
• W2067288984 hasConcept C143998085 @default.
• W2067288984 hasConcept C144301174 @default.
• W2067288984 hasConcept C146357865 @default.
• W2067288984 hasConcept C151730666 @default.
• W2067288984 hasConcept C193270364 @default.
• W2067288984 hasConcept C204232928 @default.
• W2067288984 hasConcept C207103383 @default.
• W2067288984 hasConcept C2776530083 @default.
• W2067288984 hasConcept C2776833033 @default.
• W2067288984 hasConcept C2778424827 @default.
• W2067288984 hasConcept C2780091936 @default.
• W2067288984 hasConcept C3019894029 @default.
• W2067288984 hasConcept C38180746 @default.
• W2067288984 hasConcept C44249647 @default.
• W2067288984 hasConcept C509974204 @default.
• W2067288984 hasConcept C71924100 @default.
• W2067288984 hasConcept C86803240 @default.
• W2067288984 hasConceptScore W2067288984C126322002 @default.
• W2067288984 hasConceptScore W2067288984C143998085 @default.
• W2067288984 hasConceptScore W2067288984C144301174 @default.
• W2067288984 hasConceptScore W2067288984C146357865 @default.
• W2067288984 hasConceptScore W2067288984C151730666 @default.
• W2067288984 hasConceptScore W2067288984C193270364 @default.
• W2067288984 hasConceptScore W2067288984C204232928 @default.
• W2067288984 hasConceptScore W2067288984C207103383 @default.
• W2067288984 hasConceptScore W2067288984C2776530083 @default.
• W2067288984 hasConceptScore W2067288984C2776833033 @default.
• W2067288984 hasConceptScore W2067288984C2778424827 @default.
• W2067288984 hasConceptScore W2067288984C2780091936 @default.
• W2067288984 hasConceptScore W2067288984C3019894029 @default.
• W2067288984 hasConceptScore W2067288984C38180746 @default.
• W2067288984 hasConceptScore W2067288984C44249647 @default.
• W2067288984 hasConceptScore W2067288984C509974204 @default.
• W2067288984 hasConceptScore W2067288984C71924100 @default.
• W2067288984 hasConceptScore W2067288984C86803240 @default.
• W2067288984 hasIssue "3" @default.
• W2067288984 hasLocation W20672889841 @default.
• W2067288984 hasOpenAccess W2067288984 @default.

• next